晚期NSCLC-话题@MedSci

#晚期NSCLC#

125篇内容 | 1622人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1416343, encodeId=27ec1416343b9, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=Thorac Cancer：回顾性分析多西他赛联合雷莫芦单抗（ramucirumab）二线治疗化疗联合免疫治疗进展的晚期NSCLC患者的疗效, objectType=article, longId=220896, objectId=74f1220896c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74f1220896c6, replyNumber=0, likeNumber=34, createdTime=2021-11-25, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74f1220896c6, moduleTitle=Thorac Cancer：回顾性分析多西他赛联合雷莫芦单抗（ramucirumab）二线治疗化疗联合免疫治疗进展的晚期NSCLC患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74f1220896c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416342, encodeId=bab11416342cd, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=晚期NSCLC抗血管生成治疗进展, objectType=article, longId=220768, objectId=379b220e680e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=379b220e680e, replyNumber=0, likeNumber=29, createdTime=2021-11-23, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=379b220e680e, moduleTitle=晚期NSCLC抗血管生成治疗进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=379b220e680e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416341, encodeId=6a211416341b9, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=抗血管治疗点亮晚期NSCLC一线治疗的新选择, objectType=article, longId=220753, objectId=fdb1220e5399, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdb1220e5399, replyNumber=0, likeNumber=29, createdTime=2021-11-23, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdb1220e5399, moduleTitle=抗血管治疗点亮晚期NSCLC一线治疗的新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdb1220e5399)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416340, encodeId=3666141634017, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=Cancers：EGFR/ALK阴性晚期NSCLC患者在免疫治疗获批一线治疗后的生存获益：来自真实世界研究数据, objectType=article, longId=217868, objectId=7f5c21e868c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f5c21e868c1, replyNumber=0, likeNumber=0, createdTime=2021-09-30, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f5c21e868c1, moduleTitle=Cancers：EGFR/ALK阴性晚期NSCLC患者在免疫治疗获批一线治疗后的生存获益：来自真实世界研究数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f5c21e868c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416339, encodeId=49311416339ee, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=J Clin Oncol：波齐替尼(Poziotinib)治疗HER2外显子20突变的晚期NSCLC的疗效和安全性, objectType=article, longId=217605, objectId=134f21e60540, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=134f21e60540, replyNumber=0, likeNumber=38, createdTime=2021-09-26, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=134f21e60540, moduleTitle=J Clin Oncol：波齐替尼(Poziotinib)治疗HER2外显子20突变的晚期NSCLC的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=134f21e60540)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416338, encodeId=eeb0141633899, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=J Clin Oncol：晚期NSCLC患者围手术期加用度伐单抗显著提高了1年EFS率, objectType=article, longId=214458, objectId=eb97214458d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb97214458d9, replyNumber=0, likeNumber=56, createdTime=2021-07-21, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb97214458d9, moduleTitle=J Clin Oncol：晚期NSCLC患者围手术期加用度伐单抗显著提高了1年EFS率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb97214458d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416337, encodeId=f20a141633ee6, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=Lancet respirat：同济大学3期临床试验揭示埃克替尼在EGFR突变型晚期NSCLC中的疗效, objectType=article, longId=214456, objectId=4803214456af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4803214456af, replyNumber=0, likeNumber=38, createdTime=2021-07-21, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4803214456af, moduleTitle=Lancet respirat：同济大学3期临床试验揭示埃克替尼在EGFR突变型晚期NSCLC中的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4803214456af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416336, encodeId=5282141633689, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=Lung Cancer: 纳武利尤单抗（nivolumab）治疗既往治疗过的晚期NSCLC患者的2年生存：来自法国、德国和加拿大的真实世界研究, objectType=article, longId=213586, objectId=462521358613, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=462521358613, replyNumber=0, likeNumber=0, createdTime=2021-07-02, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=462521358613, moduleTitle=Lung Cancer: 纳武利尤单抗（nivolumab）治疗既往治疗过的晚期NSCLC患者的2年生存：来自法国、德国和加拿大的真实世界研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=462521358613)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416335, encodeId=6aa91416335fc, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=ASCO2021: Nivolumab + Ipilimumab可使晚期NSCLC患者获益（CheckMate-227的4年数据）, objectType=article, longId=212499, objectId=bef02124990d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bef02124990d, replyNumber=0, likeNumber=38, createdTime=2021-06-10, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bef02124990d, moduleTitle=ASCO2021: Nivolumab + Ipilimumab可使晚期NSCLC患者获益（CheckMate-227的4年数据）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bef02124990d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416334, encodeId=8b78141633482, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=未来可期！国产PD1抑制剂助力中国晚期NSCLC二线新选择, objectType=article, longId=211116, objectId=6a65211116f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a65211116f9, replyNumber=0, likeNumber=32, createdTime=2021-05-13, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a65211116f9, moduleTitle=未来可期！国产PD1抑制剂助力中国晚期NSCLC二线新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a65211116f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416333, encodeId=6e181416333f4, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=J Thorac Oncol：纳米-紫杉醇 vs 多西他赛治疗晚期NSCLC患者的疗效, objectType=article, longId=210739, objectId=ba42210e39c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba42210e39c8, replyNumber=0, likeNumber=30, createdTime=2021-05-03, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba42210e39c8, moduleTitle=J Thorac Oncol：纳米-紫杉醇 vs 多西他赛治疗晚期NSCLC患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba42210e39c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416332, encodeId=37a11416332a9, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=2020世界肺癌大会：Keytruda联合化疗使晚期NSCLC生存期翻倍, objectType=article, longId=206761, objectId=2de1206e6140, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2de1206e6140, replyNumber=0, likeNumber=35, createdTime=2021-02-05, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2de1206e6140, moduleTitle=2020世界肺癌大会：Keytruda联合化疗使晚期NSCLC生存期翻倍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2de1206e6140)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416331, encodeId=d76e1416331a1, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle= J Clin Oncol：纳武单抗治疗晚期NSCLC的5年随访预后仍明显优于多西他赛！, objectType=article, longId=205997, objectId=a83520599eec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a83520599eec, replyNumber=0, likeNumber=48, createdTime=2021-01-23, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a83520599eec, moduleTitle= J Clin Oncol：纳武单抗治疗晚期NSCLC的5年随访预后仍明显优于多西他赛！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a83520599eec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416330, encodeId=7b981416330d7, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=JCO: 纳武利尤单抗治疗晚期NSCLC五年生存率可达化疗的5倍！, objectType=article, longId=205955, objectId=9ddd2059556a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ddd2059556a, replyNumber=0, likeNumber=32, createdTime=2021-01-22, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ddd2059556a, moduleTitle=JCO: 纳武利尤单抗治疗晚期NSCLC五年生存率可达化疗的5倍！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ddd2059556a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416329, encodeId=d22d1416329b6, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=ESMO：50%晚期NSCLC患者可获长达4年生存期度伐利尤单抗治疗显优异生存获益, objectType=article, longId=201226, objectId=f204201226fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f204201226fd, replyNumber=0, likeNumber=33, createdTime=2020-09-27, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f204201226fd, moduleTitle=ESMO：50%晚期NSCLC患者可获长达4年生存期度伐利尤单抗治疗显优异生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f204201226fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416328, encodeId=babf141632825, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=《晚期非小细胞肺癌抗血管生成药物治疗中国专家共识（2020版）》正式发布，助力晚期NSCLC临床治疗水平提升, objectType=article, longId=200723, objectId=8637200e2372, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8637200e2372, replyNumber=0, likeNumber=28, createdTime=2020-09-17, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8637200e2372, moduleTitle=《晚期非小细胞肺癌抗血管生成药物治疗中国专家共识（2020版）》正式发布，助力晚期NSCLC临床治疗水平提升, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8637200e2372)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416327, encodeId=5184141632eb9, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=AACR 2020：基于ctDNA的复合型预测模型有效预测EGFR突变阳性晚期NSCLC一线治疗PFS（FLAURA研究）, objectType=article, longId=193345, objectId=a58619334571, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a58619334571, replyNumber=0, likeNumber=36, createdTime=2020-05-03, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a58619334571, moduleTitle=AACR 2020：基于ctDNA的复合型预测模型有效预测EGFR突变阳性晚期NSCLC一线治疗PFS（FLAURA研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a58619334571)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416326, encodeId=410d14163265b, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=王燕教授：纵览EGFR突变阳性晚期NSCLC治疗，优化患者管理, objectType=article, longId=192270, objectId=8c6d1922e0a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c6d1922e0a7, replyNumber=0, likeNumber=35, createdTime=2020-04-16, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c6d1922e0a7, moduleTitle=王燕教授：纵览EGFR突变阳性晚期NSCLC治疗，优化患者管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c6d1922e0a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416325, encodeId=403314163259e, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=姚煜教授：抗血管生成单抗联合TKI治疗有望成为EGFR 21L858R突变晚期NSCLC治疗金标准, objectType=article, longId=191912, objectId=afff191912f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afff191912f3, replyNumber=0, likeNumber=44, createdTime=2020-04-11, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afff191912f3, moduleTitle=姚煜教授：抗血管生成单抗联合TKI治疗有望成为EGFR 21L858R突变晚期NSCLC治疗金标准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=afff191912f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416323, encodeId=a07c141632352, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=刘晓晴教授：EGFR敏感突变晚期NSCLC一线治疗进展颇丰，治疗药物选择需综合考虑, objectType=article, longId=190912, objectId=52ec19091290, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52ec19091290, replyNumber=0, likeNumber=40, createdTime=2020-03-28, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52ec19091290, moduleTitle=刘晓晴教授：EGFR敏感突变晚期NSCLC一线治疗进展颇丰，治疗药物选择需综合考虑, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52ec19091290)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

晚期NSCLC

2020-05-29

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

Thorac Cancer：回顾性分析多西他赛联合雷莫芦单抗（ramucirumab）二线治疗化疗联合免疫治疗进展的晚期NSCLC患者的疗效

2021-11-25

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

晚期NSCLC抗血管生成治疗进展

2021-11-23

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

抗血管治疗点亮晚期NSCLC一线治疗的新选择

2021-11-23

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

Cancers：EGFR/ALK阴性晚期NSCLC患者在免疫治疗获批一线治疗后的生存获益：来自真实世界研究数据

2021-09-30

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

J Clin Oncol：波齐替尼(Poziotinib)治疗HER2外显子20突变的晚期NSCLC的疗效和安全性

2021-09-26

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

J Clin Oncol：晚期NSCLC患者围手术期加用度伐单抗显著提高了1年EFS率

2021-07-21

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

Lancet respirat：同济大学3期临床试验揭示埃克替尼在EGFR突变型晚期NSCLC中的疗效

2021-07-21

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

Lung Cancer: 纳武利尤单抗（nivolumab）治疗既往治疗过的晚期NSCLC患者的2年生存：来自法国、德国和加拿大的真实世界研究

2021-07-02

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

ASCO2021: Nivolumab + Ipilimumab可使晚期NSCLC患者获益（CheckMate-227的4年数据）

2021-06-10

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

未来可期！国产PD1抑制剂助力中国晚期NSCLC二线新选择

2021-05-13

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

J Thorac Oncol：纳米-紫杉醇 vs 多西他赛治疗晚期NSCLC患者的疗效

2021-05-03

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

2020世界肺癌大会：Keytruda联合化疗使晚期NSCLC生存期翻倍

2021-02-05

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

J Clin Oncol：纳武单抗治疗晚期NSCLC的5年随访预后仍明显优于多西他赛！

2021-01-23

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

JCO: 纳武利尤单抗治疗晚期NSCLC五年生存率可达化疗的5倍！

2021-01-22

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

ESMO：50%晚期NSCLC患者可获长达4年生存期度伐利尤单抗治疗显优异生存获益

2020-09-27

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

《晚期非小细胞肺癌抗血管生成药物治疗中国专家共识（2020版）》正式发布，助力晚期NSCLC临床治疗水平提升

2020-09-17

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

AACR 2020：基于ctDNA的复合型预测模型有效预测EGFR突变阳性晚期NSCLC一线治疗PFS（FLAURA研究）

2020-05-03

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

王燕教授：纵览EGFR突变阳性晚期NSCLC治疗，优化患者管理

2020-04-16

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

姚煜教授：抗血管生成单抗联合TKI治疗有望成为EGFR 21L858R突变晚期NSCLC治疗金标准

2020-04-11

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

刘晓晴教授：EGFR敏感突变晚期NSCLC一线治疗进展颇丰，治疗药物选择需综合考虑

2020-03-28

科室
- - 订阅+
  - 更多科室
工具
服务